Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: A Multicenter, Randomized Phase II Study

被引：8

作者：

Peng, P. ^{[1
]}

Chen, Y. ^{[1
,2
]}

Han, G. ^{[3
]}

Meng, R. ^{[4
]}

Zhang, S. ^{[4
]}

Liao, Z. ^{[5
]}

Zhang, Y. ^{[1
]}

Gong, J. ^{[1
]}

Xiao, C. ^{[3
]}

Liu, X. ^{[3
]}

Zhang, P. ^{[1
]}

Zhang, L. ^{[1
]}

Xia, S. ^{[1
]}

Chu, Q. ^{[1
]}

Chen, Y. ^{[1
,2
]}

Zhang, L. ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Oncol, Tongji Hosp, Wuhan, Hubei, Peoples R China

[2] Wuhan Univ, Renmin Hosp, Dept Clin Oncol, Wuhan, Hubei, Peoples R China

[3] Hubei Canc Hosp, Dept Radiat Oncol, Wuhan, Hubei, Peoples R China

[4] Huazhong Univ Sci & Technol, Tongji Med Coll, Canc Ctr, Union Hosp, Wuhan, Hubei, Peoples R China

[5] Wuhan Univ, Zhongnan Hosp, Dept Radiat & Med Oncol, Wuhan, Hubei, Peoples R China

来源：

关键词：

oligometastatic NSCLC; SBRT; TKI;

D O I：

10.1016/j.jtho.2019.08.499

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA01.09

引用

页码：S250 / S251

页数：2